Page 5,856«..1020..5,8555,8565,8575,858..5,8705,880..»

Neuralstem Obtains FDA Approval To Commence Spinal Cord Injury Trial

Posted: Published on January 15th, 2013

By RTT News, January 14, 2013, 11:01:00 AM EDT (RTTNews.com) - Neuralstem Inc. ( CUR ) announced Monday that it received approval from the United States Food and Drug Administration or FDA to commence a Phase I safety trial of its lead cell therapy candidate, NSI-566, in chronic spinal cord injury patients. This open-label, multi-site study, will enroll up to eight patients with thoracic spinal cord injuries (T2-T12), who have an American Spinal Injury Association or AIS A level of impairment, between one and two years after injury. AIS A impairment refers to a patient with no motor or sensory function in the relevant segments at and below the injury, and is considered to be complete paralysis. The primary objective of the study is to determine the safety and toxicity of human spinal stem cell transplantation for the treatment of paralysis and related symptoms due to chronic spinal cord injury (SCI). The secondary objectives of the study are to evaluate graft survival in the transplant site by MRI, as well as the effectiveness of transient immunosuppression. Additionally, the study will look at exploratory objectives to evaluate the ability of human spinal cord stem cell or HSSC transplantation to positively affect … Continue reading →

Posted in Spinal Cord Injury Treatment | Comments Off on Neuralstem Obtains FDA Approval To Commence Spinal Cord Injury Trial

Gazette.Net: Neuralstem

Posted: Published on January 15th, 2013

This story was corrected on Jan. 15, 2013. An explanation follows the story. Physicians, researchers, patients and their advocates in the spinal injury field are keeping a close eye on Rockville biotech Neuralstem as it prepares to launch a Phase 1 safety trial of its stem cell treatment for chronic spinal cord injury. The Food and Drug Administration approved the trial Monday. Neuralstem plans to conduct the study on eight patients who are completely paralyzed at or below their spinal cord injuries. Its important that people understand this is very different from other methods that have gone on before, CEO Richard Garr said. This is the real deal. We have compelling data. Cells are surviving, grafting and doing what we would expect they would do. The FDA go-ahead follows Neuralstems report in October that rats given the stem cell product, NSI-566, seven days after suffering an ischemic stroke showed improvement in motor and neurological tests. Should this prove to be successful, it will allow for some regeneration of human spinal cord cells and for people to regain function. It will be an incredible breakthrough, with huge implications for the health care market, said Paul Tobin, president and CEO of the … Continue reading →

Posted in Spinal Cord Injury Treatment | Comments Off on Gazette.Net: Neuralstem

Study on Parkinson's may lead to earlier diagnosis

Posted: Published on January 15th, 2013

MUMBAI: A new study could help earlier diagnosis of Parkinson's disease. According to a study by Newcastle University, researchers said that even in early stages of the disease people may experience symptoms. While movement-- motor problems are the main symptom of Parkinson's disease, non-motor problems such as drooling, anxiety and bowel problems affect a large number of patients, and begin sooner than previously thought. Earlier diagnosis could lead to earlier treatment and therefore allow patients to have a better quality of life. In the study, published on Tuesday in the medical journal, American Academy of Neurology, researchers from Newcastle University compared 159 people with newly-diagnosed Parkinson's disease to 99 people of similar ages who did not have the disease. Participants were asked whether they experienced any of the 30 non-motor symptoms screened for, including sexual problems, sleep problems and gastrointestinal problems. Study author Dr Tien K Khoo said: ""Often people don't even mention these symptoms to their doctors, and doctors don't ask about them, yet many times they can be treated effectively."" The people with Parkinson's disease had an average of eight of the non-motor problems, compared to three non-motor symptoms for the people who did not have the disease. … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Study on Parkinson's may lead to earlier diagnosis

Breakthrough by North-East researchers could lead to earlier diagnosis of Parkinson's

Posted: Published on January 15th, 2013

Breakthrough by North-East researchers could lead to earlier diagnosis of Parkinson's 1:00am Tuesday 15th January 2013 in News By Barry Nelson, Health Editor A NEW study by North-East researchers could help earlier diagnosis of Parkinson 's disease. While movement - motor - problems are the main symptom of Parkinson's, non-motor problems such as drooling, anxiety and bowel problems affect a large number of patients and begin sooner than previously thought. Earlier diagnosis could lead to earlier treatment and allow patients to have a better quality of life. In the study, published in the journal Neurology, the medical journal of the American Academy of Neurology, researchers from Newcastle University compared 159 people with newly-diagnosed Parkinson's disease to 99 people of similar ages who did not have the disease. Participants were asked whether they experienced any of the 30 non-motor symptoms screened for, including sexual problems, sleep problems and gastrointestinal problems. Study author Dr Tien K. Khoo said: "Often people don't even mention these symptoms to their doctors, and doctors don't ask about them, yet many times they can be treated effectively." The people with Parkinson's disease had an average of eight of the non-motor problems, compared to three non-motor symptoms for … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Breakthrough by North-East researchers could lead to earlier diagnosis of Parkinson's

Parkinson's can lead to anxiety and other non-motor symptoms, even early on

Posted: Published on January 15th, 2013

Jan. 14, 2013 While movement problems are the main symptom of Parkinson's disease, a new study shows that even early in the course of disease people frequently experience many non-motor symptoms such as drooling, anxiety and constipation. The study is published in the January 15, 2013, print issue of Neurology, the medical journal of the American Academy of Neurology. "Oftentimes people with early Parkinson's don't even mention these symptoms to their doctors, and doctors don't ask about them, yet many times they can be treated effectively," said study author Tien K. Khoo, PhD, of Newcastle University in the United Kingdom. The study compared 159 people with newly diagnosed Parkinson's disease to 99 people of similar ages who did not have the condition. Participants were asked whether they experienced any of the 30 non-motor symptoms screened for, including sexual problems, sleep problems and gastrointestinal problems. Those with Parkinson's disease had an average of eight of the non-motor problems, compared to three for the people who did not have the disorder. Among the most common symptoms for those with Parkinson's disease were drooling, urinary urgency, constipation, anxiety and a reduced sense of smell. These likely represent other symptoms of Parkinson's that may … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Parkinson's can lead to anxiety and other non-motor symptoms, even early on

Opexa Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement

Posted: Published on January 15th, 2013

THE WOODLANDS, Texas--(BUSINESS WIRE)-- Opexa Therapeutics, Inc. (OPXA), a company developing Tcelna, a novel T-cell therapy for multiple sclerosis (MS), today announced that it has received a letter from The NASDAQ Stock Market LLC notifying the Company that it has regained full compliance with the NASDAQ Capital Market's minimum bid price continued listing requirement. The letter noted that as of December 31, 2012, the Company evidenced a closing bid price of its common stock in excess of the $1.00 minimum requirement for at least ten consecutive trading days. Accordingly, the Company has regained compliance with NASDAQ Marketplace Rule 5550(a)(2) and NASDAQ considers the matter closed. The Company has submitted its plan to regain compliance with NASDAQs minimum stockholders equity listing standard set forth in listing rule 5550(b)(1), and NASDAQ is currently reviewing the plan. If the Companys plan is accepted, NASDAQ may grant an extension until May 25, 2013 for the Company to regain compliance with the minimum stockholders equity standard. About Opexa Opexa Therapeutics, Inc. is dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases such as MS. The Companys leading therapy, Tcelna, is a personalized cellular immunotherapy treatment that is in late stage … Continue reading →

Posted in MS Treatment | Comments Off on Opexa Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement

Stem Cell Research News Project – Video

Posted: Published on January 15th, 2013

Stem Cell Research News Project description By: TheFixFactor … Continue reading →

Posted in Stem Cell Research | Comments Off on Stem Cell Research News Project – Video

Public invited to learn about cord blood banking

Posted: Published on January 15th, 2013

SCOTTSDALE, Ariz. -- Public and family cord blood banking is now available at Scottsdale Healthcare Shea Medical Center, which is planning a free community presentation Jan. 29 at 9 a.m. featuring Matthew Farrow, recipient of the world's first successful umbilical cord blood transplant, Dr. Hal Broxmeyer, a pioneer in the cord blood banking and transplant field, and NBA basketball legend Julius "Dr. J" Erving, an ardent supporter of cord blood transplant science. The free event is from 9 a.m. to 11 a.m. at Scottsdale Healthcare Shea Medical Center, 9003 E. Shea Blvd., in Scottsdale. Expectant couples delivering babies at Scottsdale Healthcare Shea Medical Center now have the option to donate their baby's umbilical cord blood to a public cord blood bank. Cord blood can be used for life-saving stem cell transplants to treat more than 70 diseases including leukemia, lymphoma and sickle cell anemia. Speakers at the cord blood banking community event include: Dr. Hal Broxmeyer, recognized as a founder of the field of cord blood stem cell banking and transplantation. Matthew Farrow, recipient of the world's first successful umbilical cord blood transplant in 1988. Stephen Sprague, one of the world's first adult patients to benefit from a cord blood … Continue reading →

Posted in Stem Cell Research | Comments Off on Public invited to learn about cord blood banking

Western University researchers identify new genetic mutation for ALS

Posted: Published on January 15th, 2013

Public release date: 15-Jan-2013 [ | E-mail | Share ] Contact: Kathy Wallis kwallis3@uwo.ca 519-661-2111 x81136 University of Western Ontario Researchers at Western University in London, Canada, have identified a new genetic mutation for amyotrophic lateral sclerosis (ALS), opening the door to future targeted therapies. Dr. Michael Strong, a scientist with Western's Robarts Research Institute and Distinguished University Professor in Clinical Neurological Sciences at the Schulich School of Medicine & Dentistry, and colleagues found that mutations within the ARHGEF28 gene are present in ALS. When they looked across both familial and sporadic forms of the disease, they found that virtually all cases of ALS demonstrated abnormal inclusions of the protein that arises from this gene. The research is published online in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneratio, the official journal of The World Federation of Neurology Research Group on Motor Neuron Diseases. ALS, sometimes called Lou Gehrig's disease, is a progressive disease that affects the motor neurons that connect the brain to muscles throughout the body. It is a devastating disease with 90 per cent of patients dying within five years of diagnosis. As many as 30,000 Americans and 2,000 Canadians are living with ALS. Strong's team is convinced ALS … Continue reading →

Comments Off on Western University researchers identify new genetic mutation for ALS

Western University researchers discover genetic mutation linked to Lou Gehrig's disease

Posted: Published on January 15th, 2013

Researchers at Western University have identified a new genetic mutation that may open doors to better understand, and potentially treat, Lou Gehrigs disease. Dr. Michael Strong, a scientist with Westerns Robarts Research Institute and professor at the Schulich School of Medicine and Dentistry, found that mutations within the ARHGEF28 gene are present in amyotrophic lateral sclerosis (ALS). His work is published online in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneratio, the official journal of The World Federation of Neurology Research Group on Motor Neuron Diseases. Lou Gehrigs disease affects the motor neurons that connect the brain to muscles throughout the body and 90% of its victims die swithin 5 years of diagnosis. As many as 30,000 Americans and 2,000 Canadians are living with ALS. Every time we look at a cell degenerating, this particular protein was deposited abnormally in the cell. It was a common denominator, explains Strong, who is also the dean of Schulich Medicine and Dentistry. Working with Dr. Rob Hegele at Robarts, we found there was a genetic mutation in the gene coding for this protein. So its a huge discovery. More than a dozen genes have been linked in other research to ALS. The research was funded … Continue reading →

Comments Off on Western University researchers discover genetic mutation linked to Lou Gehrig's disease

Page 5,856«..1020..5,8555,8565,8575,858..5,8705,880..»